Since their discovery, antibiotics and other antimicrobial agents have saved millions of lives and significantly eased patients’ suffering. However, over time, micro-organisms have developed resistance to existing antibiotics making infections difficult, if not impossible, to treat. The recent appearance of multiple-resistant bacterial infections has radically increased the necessity for new antibiotic discovery.
As part of a three-year programme, the joint research facility will utilise CABI’s unique collection of fungi gathered from all parts of the world, to screen for potential new antibiotics. Although the first natural product antibiotic to be used clinically, penicillin, was isolated from a fungus, these organisms have not been as extensively evaluated as bacteria as sources of new drugs for treating infections and so there is great potential for discovery in CABI’s 28,000 organism collection.
Furthermore, over the past 25 years companies have concentrated on using chemistry-based approaches to modify recognised antibiotic structures. However, the use of natural products, from fungi, which have evolved from millions of years of competition against bacteria is likely to lead to products with new modes of antibiotic action that disease-causing bacteria cannot counter. This new joint facility aims to harness these natural chemical compounds from fungi to offer potential new antibiotics. Similarly, compounds that have proven health benefits when taken in the diet (so-called nutraceuticals) are also likely to be found in fungi and the new joint research facility will also screen the collection for new nutraceuticals.
Professor Peter Bramley and Dr Paul Fraser in the School of Biological Sciences at Royal Holloway and Dr Trevor Nicholls, CEO and Dr Joan Kelley Executive Director of CABI are managing the project. Professor Bramley and Dr Fraser’s extensive experience in molecular biology and analytical methodologies will be applied to state-of-the-art screening techniques for the discovery of new compounds and the manipulation, recombination and expression of their biosynthetic pathways to bioengineer new, related compounds. Dr Nicholls’ experience in the biotechnology industry and Dr Kelley’s expertise and knowledge of mycology and biodiversity will direct the research to identify strains which are likely to be more biochemically diverse and commercially valuable for screening.
Professor Bramley commented, “This joint initiative lays the foundations for a long term collaboration with potential strategic benefits, both research and commercial. A major focus will be the search for new antibiotics and nutraceuticals, for which there is now increasing commercial, nutritional and medical demand.”
Dr Trevor Nicholls, CEO CABI added, “This is a really exciting partnership and we are looking forward to working with the expertise of the scientists at Royal Holloway. We are hopeful that our collaboration will prove the winning formula for discovering new drugs to fight cancers, diseases and resistant strains of infections such as MRSA.”
The joint facility is located in the Royal Holloway’s School of Biosciences and houses a new state-of-the-art mass spectrometer. As part of this collaboration, two technicians will be employed and a PhD studentship funded.
Royal Holloway has also obtained early stage seed fund investment from the London Development Agency backed WestFocus PARK Fund, to commercialise any potential new discoveries emerging from this project. The project team will work closely with the Research & Enterprise department at Royal Holloway to protect, manage and exploit any new intellectual property.
First time-lapse footage of cell activity during limb regeneration
25.10.2016 | eLife
Phenotype at the push of a button
25.10.2016 | Institut für Pflanzenbiochemie
Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.
This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
26.10.2016 | Materials Sciences
26.10.2016 | Health and Medicine
26.10.2016 | Physics and Astronomy